<DOC>
	<DOCNO>NCT00001720</DOCNO>
	<brief_summary>Bones grow stay strong continuous process formation ( build ) resorption ( break ) . When bone form resorbed , density ( level calcium ) bone increase bone become strong . However , bone resorb form density bone decrease bone become weak . This condition call osteoporosis . Osteoporosis rare serious condition child . Childhood osteoporosis occur without know cause ( idiopathic juvenile osteoporosis ) . Children osteoporosis suffer pain , inability stay active , increased amount broken bone , include fracture spine . Even mild childhood osteoporosis may long-term consequence since individual achieve less normal bone composition ( peak bone mass ) first 20-30 year life may increase risk osteoporosis adult . Alendronate ( Fosamax ) drug work stop bone resorption ( break ) . It use treat post-menopausal osteoporosis , male osteoporosis adult osteoporosis due long-term steroid therapy . The goal study determine effectiveness alendronate child idiopathic juvenile osteoporosis . Researchers believe child treat alendronate improve bone strength decrease amount fracture cause osteoporosis .</brief_summary>
	<brief_title>Treatment Childhood Osteoporosis With Alendronate ( Fosamax )</brief_title>
	<detailed_description>Osteoporosis rare serious condition child . One least well understood form childhood osteoporosis idiopathic juvenile osteoporosis . Affected child suffer pain , decrease activity tolerance , increase fracture , include vertebral compression fracture . Even mild childhood osteoporosis may long-term consequence since individual achieve low peak bone mass first 2-3 decade life may increase risk osteoporosis adult . Alendronate ( Fosamax ( Trademark ) , Merck &amp; Co. ) , aminobisphosphonate , potent inhibitor bone resorption . It use treat postmenopausal osteoporosis , idiopathic male osteoporosis , glucocorticoid induce osteoporosis adult . The goal protocol evaluate effectiveness Alendronate child glucocorticoid induced idiopathic juvenile osteoporosis use double-blind , randomize , placebo-controlled study design . We hypothesize child treat drug improvement bone mineral density decrease osteoporotic fracture .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>INCLUSION CRITERIA : Chronological age : 6.0 17.0 year . Study population restrict child great 12 year age 8 patient complete 6 month study safety data available comparable study . AP Lumbar spine bone mineral density less equal 2 standard deviation age match control ( zscore ) use Hologic QDR machine . Normative data publish Faulkner use calculate Zscores . Patients Idiopathic Juvenile Osteoporosis , osteoporosis ( BMD le 2 SD compare agematched control ) child identifiable etiology . Children IJO delay puberty zscore calculate basis bone age . EXCLUSION CRITERIA : Inability swallow pill comply administration instruction . Upper gastrointestinal tract disease . Creatinine clearance great equal 35 mL per min per 1.73 square meter . Prior treatment bisphosphonates . Concurrent therapy oral aspirin salicylate contain compound , exclude delayedrelease salicylates act distal gastrointestinal tract ( example , mesalamine , sulfasalazine , etc ... ) . Hypocalcemia . Treatment hGH calcitonin precede 6 month . Inability undergo dual energy xray absorptiometry . Positive pregnancy test . In female , sexual activity without effective method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Glucocorticoids</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Vertebral Fracture</keyword>
	<keyword>Childhood Osteoporosis</keyword>
</DOC>